The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression

被引:193
|
作者
Burnstock, Geoffrey [1 ,2 ,3 ]
Knight, Gillian E. [1 ]
机构
[1] UCL, Sch Med, Auton Neurosci Ctr, Rowland Hill St, London NW3 2PF, England
[2] Univ Melbourne, Dept Pharmacol & Therapeut, Melbourne, Vic, Australia
[3] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia
关键词
Pain; Infection; Cancer; CNS disorders; Cardiovascular; Airways; Diabetes; Kidney; Bladder; Liver; Gut; Immune cells; BRILLIANT BLUE G; TYPE-2; DIABETIC-RATS; P2X(7) RECEPTOR; PURINERGIC RECEPTORS; EXTRACELLULAR ATP; MOUSE MODEL; NLRP3; INFLAMMASOME; IN-VIVO; CELL INVASION; ANIMAL-MODEL;
D O I
10.1007/s11302-017-9593-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Seven P2X ion channel nucleotide receptor subtypes have been cloned and characterised. P2X7 receptors (P2X7R) are unusual in that there are extra amino acids in the intracellular C terminus. Low concentrations of ATP open cation channels sometimes leading to cell proliferation, whereas high concentrations of ATP open large pores that release inflammatory cytokines and can lead to apoptotic cell death. Since many diseases involve inflammation and immune responses, and the P2X7R regulates inflammation, there has been recent interest in the pathophysiological roles of P2X7R and the potential of P2X7R antagonists to treat a variety of diseases. These include neurodegenerative diseases, psychiatric disorders, epilepsy and a number of diseases of peripheral organs, including the cardiovascular, airways, kidney, liver, bladder, skin and musculoskeletal. The potential of P2X7R drugs to treat tumour progression is discussed.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 50 条
  • [41] The role of P2X7 in pain and inflammation
    Jane P Hughes
    Jonathan P Hatcher
    Iain P Chessell
    Purinergic Signalling, 2007, 3 : 163 - 169
  • [42] P2X7 receptor in inflammation and pain
    Hu, Shi-qi
    Hu, Jia-ling
    Zou, Fei-long
    Liu, Ji-peng
    Luo, Hong-liang
    Hu, Dong-xia
    Wu, Li-dong
    Zhang, Wen-jun
    BRAIN RESEARCH BULLETIN, 2022, 187 : 199 - 209
  • [43] The P2X7 Receptor in Infection and Inflammation
    Di Virgilio, Francesco
    Dal Ben, Diego
    Sarti, Alba Clara
    Giuliani, Anna Lisa
    Falzoni, Simonetta
    IMMUNITY, 2017, 47 (01) : 15 - 31
  • [44] Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis
    Mckenzie, Andre D. J.
    Garrett, Taylor R.
    Werry, Eryn L.
    Kassiou, Michael
    ACS CHEMICAL NEUROSCIENCE, 2022, 13 (10): : 1479 - 1490
  • [45] P2X7 Receptor Signaling Pathway as a Therapeutic Target for Neurodegenerative Diseases
    Takenouchi, Takato
    Sekiyama, Kazunari
    Sekigawa, Akio
    Fujita, Masayo
    Waragai, Masaaki
    Sugama, Shuei
    Iwamaru, Yoshifumi
    Kitani, Hiroshi
    Hashimoto, Makoto
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2010, 58 (02) : 91 - 96
  • [46] The purinergic receptor P2X7, a new therapeutic target in Alzheimer disease
    Martin, Elodie
    Kanellopoulos, Jean
    Fontaine, Bertrand
    Delatour, Benoit
    Delarasse, Cecile
    M S-MEDECINE SCIENCES, 2019, 35 (02): : 97 - 99
  • [47] The P2X7 purinergic receptor: An emerging therapeutic target in cardiovascular diseases
    Chen, Zhe
    He, Lu
    Li, Lanfang
    Chen, Linxi
    CLINICA CHIMICA ACTA, 2018, 479 : 196 - 207
  • [48] Effects of antidepressants on P2X7 receptors
    Wang, Wei
    Xiang, Zheng-Hua
    Jiang, Chun-Lei
    Liu, Wei-Zhi
    Shang, Zhi-Lei
    PSYCHIATRY RESEARCH, 2016, 242 : 281 - 287
  • [49] P2X7 Receptor Signaling Pathway as a Therapeutic Target for Neurodegenerative Diseases
    Takato Takenouchi
    Kazunari Sekiyama
    Akio Sekigawa
    Masayo Fujita
    Masaaki Waragai
    Shuei Sugama
    Yoshifumi Iwamaru
    Hiroshi Kitani
    Makoto Hashimoto
    Archivum Immunologiae et Therapiae Experimentalis, 2010, 58 : 91 - 96
  • [50] The P2X7 receptor: a new therapeutic target in Alzheimer's disease
    Illes, Peter
    Rubini, Patrizia
    Huang, Lumei
    Tang, Yong
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2019, 23 (03) : 165 - 176